Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

July 2018; 5 (4) Clinical/Scientific NotesOpen Access

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy

Goran Rakocevic, Ubaldo Martinez-Outschoorn, Marinos C. Dalakas
First published April 5, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000460
Goran Rakocevic
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ubaldo Martinez-Outschoorn
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marinos C. Dalakas
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
Goran Rakocevic, Ubaldo Martinez-Outschoorn, Marinos C. Dalakas
Neurol Neuroimmunol Neuroinflamm Jul 2018, 5 (4) e460; DOI: 10.1212/NXI.0000000000000460

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1325

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Article Figures & Data

Tables

  • Table

Letters: Rapid online correspondence

  • Author Response: Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
    • Marinos C. Dalakas, Professor of Neurology, Thomas Jefferson University Philadelphia, PA and National and Kapodistrian University of Athens Medical School, Athens Greece
    • Ubaldo Martinez-Outschoorn, Associate Professor, Thomas Jefferson University Philadelphia, PA
    • Goran Rakocevic, Associate Professor, Thomas Jefferson University Philadelphia, PA
    Submitted May 04, 2018
  • RE: Obinutuzumab, a new anti-CD20 antibody, is active and effective in anti-MAG antibody polyneuropathy.
    • Chiara Briani, Neurologist, Department of Neurosciences, University of Padova, Italy
    • Andrea Visentin, Hematologist, Hematology Unit, Department of Medicine, University of Padova, Italy
    • Alessandro Salvalaggio, Neurology resident, Department of Neurosciences, University of Padova, Italy
    • Mario Cacciavillani, Neurophysiologist, CEMES, Data-Medica Group, Padova
    • Livio Trentin, Hematologist, Hematology Unit, Department of Medicine, University of Padova, Italy
    Submitted April 16, 2018
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Classification of evidence
    • Patients and treatments
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder

Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Immunology
  • Autoimmune diseases
  • Class IV
  • Peripheral neuropathy

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Views & Reviews
    Targeting B Cells to Modify MS, NMOSD, and MOGAD
    Part 1
    Jonas Graf, Jan Mares, Michael Barnett et al.
    Neurology: Neuroimmunology & Neuroinflammation, December 16, 2020
  • Clinical/Scientific Notes
    LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY
    L. Benedetti, C. Briani, D. Franciotta et al.
    Neurology, November 17, 2008
  • Article
    The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
    Francesca Castellani, Andrea Visentin, Marta Campagnolo et al.
    Neurology: Neuroimmunology & Neuroinflammation, April 13, 2020
  • Views & Reviews
    The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy
    Jean-Michel Vallat, Mathilde Duchesne, Philippe Corcia et al.
    Neurology, December 04, 2020
Neurology - Neuroimmunology Neuroinflammation: 10 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise